Hedge Fund Manager Ubben Commits To Valeant RelationshipMark Melin
Jeffrey Ubben and his Hedge fund ValueAct are more strongly committed to their second largest holding, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), than ever before.
Ubben made negative comments about Valeant, Allergan deal
After ValueAct’s representative on the Valeant board, Mason Morfit, stepped down from his board seat in May to devote time to ValueAct’s largest holding, Microsoft Corporation (NASDAQ:MSFT), and Ubben subsequently made negative comments . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible